Searched for
INNOVATIVE DRUGS
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...
AI saves clinicians time but most lack training, survey findsArtificial intelligence is helping doctors and nurses save time and see more patients. However, a Philips survey shows most healthcare work...
India willing to open its market to high-quality, innovative pharma products, says commerce ministerIndia is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
“Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
Could space-grown stem cells unlock faster cancer treatments and revolutionize organ regeneration breakthroughs? NASA’s ISS experiments are revealing surprising answers about the power of microgravity medicineSpace stem cell research is rapidly changing cancer treatment and regenerative medicine worldwide. Scientists aboard the International Spac...
From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
Mark Zuckerberg's philanthropic venture unveils AI world model for drug discoveryBiohub, a venture by Mark Zuckerberg and Priscilla Chan, has launched a protein biology world model. This advanced AI tool aims to speed up...
All central science and innovation schemes to be rolled out in West BengalMajor central science and innovation schemes are now active in West Bengal. Union Minister Jitendra Singh met with West Bengal Chief Minist...
Global firms bring more work in-house at India hubs on AI boostThe shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...
Global firms bring more work in-house at India hubs on AI boostGlobal firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...
An SNL 'All Drug Olympics?' Not quite. But these Enhanced Games are no jokeThe "Enhanced Games" in Las Vegas allows athletes to use performance enhancers, aiming to challenge mainstream sports' anti-doping efforts ...
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...